CIDP Assessment Tools Infographic

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Assessment Tools
  • CIDP

A number of tools are available to assess disease severity and progression in patients with peripheral neuropathies such as CIDP. Gain a better understanding of four of these tools.

Featured Video

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
15:31 MIN
  • CIDP
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

Our Experts

David R. Cornblath, MD
Johns Hopkins University, Baltimore, MD, USA
David R. Cornblath, MD
David R. Cornblath, MD
Johns Hopkins University, Baltimore, MD, USA
  • GBS
David R. Cornblath received his MD from Case Western Reserve University and completed his residency and fellowship at the Hospital of the University of Pennsylvania under Prof. A.K. Asbury.
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Richard A. Lewis, MD
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
  • CIDP
  • GBS
  • MMN
Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.
Jeffrey A. Allen, MD
University of Minnesota
Jeffrey A. Allen, MD
University of Minnesota
  • CIDP
  • MMN
Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis.
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
Nabil Moumane, MD
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
  • CIDP
  • MMN
Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.
Back to Top